Understanding how certain cells change in systemic sclerosis
Official title: The Lipofibroblast to Myofibroblast Transition in Systemic Sclerosis
Funded at University of California Los Angeles · NIH-10950562 · Data updated 2026-11-12
This study is looking at how certain cells change in people with systemic sclerosis, a rare autoimmune disease that can cause lung problems, to find new ways to treat the lung issues that come with it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $110,959 |
| NIH project number | 1K38HL175027-01 |
| Project ID | NIH-10950562 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with systemic sclerosis, particularly those experiencing interstitial lung disease.
✕Less likely to help
Patients with other forms of lung disease unrelated to systemic sclerosis may not benefit from this research.
What this research studies
This research investigates the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune disease that can lead to severe lung complications. By studying the mechanisms that drive this cellular change, the research aims to identify new treatment targets for systemic sclerosis-associated interstitial lung disease. The approach involves examining the role of PPARg, a key regulator in this process, and how its regulation affects fibrosis. Patients may benefit from insights that could lead to more effective therapies for their condition.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reverse lung fibrosis in patients with systemic sclerosis.
How similar studies have gone: Previous studies have shown promise in targeting the lipofibroblast to myofibroblast transition, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Young, Arissa C — University of California Los Angeles
- Study coordinator: Young, Arissa C
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
From proteins and genes to new treatments for scar-related lung disease
A large NIH grant is working to map the proteins in the lungs of people with systemic sclerosis to find new targets for drugs that could slow or stop lung fibrosis.
-
Cell-level clues to skin scarring in systemic sclerosis and localized scleroderma
A study at the University of Pittsburgh is looking at how skin cells and their helpers change at the DNA level in adults and children with systemic sclerosis to find new targets to reduce scarring.
-
Clinical-Translational Studies in Skin, Lung, and Blood Vessel Problems in Systemic Sclerosis
A NIH grant supports coordinated efforts to understand and improve health for people with systemic sclerosis and related conditions by sharing resources, data, and pilot projects at MUSC.
-
Role of A20 and DREAM in fat cells and skin scarring in systemic sclerosis
A research project at the University of Michigan looks at how differences in fat tissue and blood vessels relate to skin scarring in systemic sclerosis, with the aim of finding new ways to treat or prevent fibrosis.
-
Vasculopathy in Systemic Sclerosis and Lung Disease in Adults
A study in adults with systemic sclerosis will look at how blood vessels in the lungs and body relate to the development of lung disease, with the aim of finding new ways to prevent it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.